Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection

被引:42
|
作者
Meyers, CD
Kashyap, ML
机构
[1] Vet Affairs Hlth Care Syst, Atherosclerosis Res Ctr, Long Beach, CA 90822 USA
[2] Vet Affairs Hlth Care Syst, Gerontol Sect, Long Beach, CA 90822 USA
[3] Univ Calif Irvine, Div Cardiol, Irvine, CA USA
关键词
high-density lipoproteins; apolipoprotein Al; reverse cholesterol transport; atherosclerosis;
D O I
10.1097/01.hco.0000126582.27767.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Despite the best efforts in reduction of low-density lipoprotein cholesterol, most cardiovascular events are not being prevented. Because high-density lipoprotein (HDL) promotes reverse cholesterol transport and other antiatherogenic effects, interventions aimed at raising HDL cholesterol or mimicking its beneficial effects may greatly improve treatment and prevention of cardiovascular disease. This article reviews the antiatherogenic effects of HDL, recent insights into the mechanisms of action of currently available, and emerging HDL-based therapies. Recent findings New insights into the basic science of HDIL function and metabolism (such as the discovery of beta-chain ATIP synthase as a hepatic catabolic HDL receptor) are further characterizing the importance of HDIL in atheroprotection and identifying novel targets of drug development. Nicotinic acid, fibrates, statins, and thiazolidinediones not only increase HDIL cholesterol but also alter HDIL subpopulation size and composition. Furthermore, these drugs promote direct antiatherogenic effects of HDL (antioxidation, anti-inflammation, antithrombotic effects, endothelial stabilization). Emerging HDL-raising therapies (such as cholesteryl ester transfer protein inhibitors and 1,2-dimyristoyl-sn-glycero-phosphocholine) and novel interventions that mimic HDL's beneficial effects (such as apolipoprotein Al-milano. and apolipoprotein Al mimetic peptides) are proving beneficial in animal and human studies. Summary An understanding of the atheroprotective mechanisms of HDL is essential for the rational use of currently available drugs and directed development of new drugs. Increasing total HDL cholesterol may not be as important as increasing the functional properties of HDL. Cardiovascular disease treatment and prevention can be improved by combining current low-density lipoprotein-based strategies with effective HDL-based interventions.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 50 条
  • [41] High-Density Lipoproteins Put Out the Fire
    Moore, Kathryn J.
    Fisher, Edward A.
    CELL METABOLISM, 2014, 19 (02) : 175 - 176
  • [42] Treatment options for low high-density lipoproteins
    Hafiane, Anouar
    Kellett, Samantha
    Genest, Jacques
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (02) : 134 - 139
  • [43] Latest Insights Into High-Density Lipoprotein Functions
    Noto, Hiroshi
    ENDOCRINOLOGIST, 2009, 19 (04) : 179 - 186
  • [44] High-Density Lipoproteins and Acute Kidney Injury
    Smith, Loren E.
    SEMINARS IN NEPHROLOGY, 2020, 40 (02) : 232 - 242
  • [45] Antiatherogenic effects of high-density lipoproteins: mechanisms
    Barter, PJ
    Rye, KA
    Clay, MA
    Ashby, D
    Baker, PW
    Xia, P
    Gamble, JR
    Vadas, MA
    ATHEROSCLEROSIS XI, 1998, 1155 : 125 - 133
  • [46] Lymphatic transport of high-density lipoproteins and chylomicrons
    Randolph, Gwendalyn J.
    Miller, Norman E.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (03) : 929 - 935
  • [47] High-Density Lipoproteins From Function to Therapy
    Zheng, Chunyu
    Aikawa, Masanori
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (23) : 2380 - 2383
  • [48] High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study
    Asztalos, BF
    CURRENT OPINION IN CARDIOLOGY, 2004, 19 (04) : 385 - 391
  • [49] Dysfunctional High-Density Lipoprotein and Atherosclerosis
    Shawn Ragbir
    John A. Farmer
    Current Atherosclerosis Reports, 2010, 12 : 343 - 348
  • [50] Dysfunctional High-Density Lipoprotein and Atherosclerosis
    Ragbir, Shawn
    Farmer, John A.
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) : 343 - 348